Offer your patients predictable bleed control and an established safety profile
*The pharmacokinetics of IXINITY have been evaluated in 32 previously treated patients (PTPs) ≥12 years of age with severe to moderately severe hemophilia B.1
References: 1. IXINITY [coagulation factor IX (recombinant)]. Prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022. 2. Data on file. Chicago, IL, Medexus Pharma, Inc.